CDK6 and acute myeloid leukemia: Hypothetically, CDK6 inhibitors (CDK6i) could be another potential drug target approach for managing AML (Fig. 1A), potentially synergizing with upstream FLT3i, or be effective on its own for treating FLT3i-resistant patients (Fig. 1A).